AQP4 and myeloid sarcoma: In a Japanese cohort studied by Watanabe9, P100 was delayed over 121 ms (30′ check-size) in only 1/6 (17%) AQP4+ patients with non-absent VEP response, compared to 28/64 (44%) MS patients with delayed latency.